Using patient-derived organoids to predict lung cancer treatment response
Patient-derived Organoids of Lung Cancer to Test Drug Response
This study is testing if tiny lab-grown versions of lung tumors can help doctors figure out which cancer treatments will work best for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Geneva Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Geneva) |
| Trial ID | NCT03979170 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of patient-derived organoid (PDO) models in predicting the response of lung cancer patients to anti-cancer drugs. By establishing organoids from tumor biopsies, researchers will analyze the tumor characteristics and test the organoids' sensitivity to various chemotherapy regimens. The study will involve 50 cases over a period of three years, focusing on the consistency and accuracy of these models in guiding personalized treatment plans for lung cancer patients.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with histologically proven lung cancer who can provide biopsy or surgical samples.
Not a fit: Patients who are under 18 years of age or unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective chemotherapy regimens for lung cancer patients.
How similar studies have performed: Other studies using patient-derived organoids have shown promise in predicting treatment responses, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically proven lung cancer * Age ≥ 18 * Written informed and signed consent * Accessible to biopsy and/or surgery sample of metastasis and/or primitive tumour Exclusion Criteria: * Less than 18 years of age * Not able to give informed consent (language, intellectual capacities, etc.) * Not accessible to biopsy and/or surgery sample * Not enough lung tissue for a histological analysis or the remaining lung tissue is not enough to perform a routine pathological analysis.
Where this trial is running
Geneva
- Geneva University Hospitals — Geneva, Switzerland (Recruiting)
Study contacts
- Study coordinator: Veronique SERRE-BEINIER, PhD
- Email: veronique.serre-beinier@hcuge.ch
- Phone: (0)223795107
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.